Esketamine Reduces Lung Injury Caused by Limb Ischemia-Reperfusion by Regulating Oxidative Stress via the TLR4/NF-κB/NLRP3 Pathway.
Endocrine, metabolic & immune disorders drug targets April 29, 2025 Meng Wang, Qian Ma, Wenjuan Wang et al. 1 citation
Esketamine reduced acute lung injury caused by limb ischemia-reperfusion in a rat model. Treatment lowered pulmonary edema, inflammatory cell infiltration, and oxidative stress, as shown by decreased MDA and increased SOD levels. It also reduced inflammatory cytokines in bronchoalveolar fluid and serum. The protective effect involved suppression of the TLR4/NF-κB/NLRP3 pathway; activating that pathway with LPS reversed esketamine's benefits. The findings suggest esketamine may be a potential therapy for acute lung injury.